Cingulate Announces Pricing of $7.5 Million Public Offering
02 févr. 2024 09h15 HE
|
Cingulate Inc.
KANSAS CITY, Kan., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) (“Cingulate,” the “Company,” “we,” “our” or “us”), a biopharmaceutical company utilizing its proprietary Precision...
Journal of the American Academy of Dermatology Publishes ZORYVE (roflumilast) Foam, 0.3% Results for Seborrheic Dermatitis from Pivotal Phase 3 Trial
29 janv. 2024 08h00 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced that JAAD published positive results from the pivotal Phase 3 STRATUM trial evaluating ZORYVE (roflumilast) foam, 0.3%.
BioNTech und DualityBio starten zulassungsrelevante Phase-3-Studie mit Antikörper-Wirkstoff-Konjugat-Kandidat BNT323/DB-1303 bei metastasiertem Brustkrebs
22 janv. 2024 06h45 HE
|
BioNTech SE
Der Start der zulassungsrelevanten Phase-3-Studie mit BNT323/DB-1303 basiert auf positiven Daten zur Sicherheit und Wirksamkeit aus einer Phase-1/2-Studie bei Brustkrebspatientinnen und -patienten mit...
BioNTech and DualityBio Initiate Pivotal Phase 3 Trial Of Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Metastatic Breast Cancer
22 janv. 2024 06h45 HE
|
BioNTech SE
The pivotal Phase 3 trial with BNT323/DB-1303 follows positive Phase 1/2 safety and efficacy data in patients with Human Epidermal Growth Factor Receptor 2 (“HER2”)-expressing advanced solid tumors...
Avenue Therapeutics Reaches Final Agreement with the U.S. FDA for the Phase 3 Safety Study for IV Tramadol
04 janv. 2024 08h30 HE
|
Avenue Therapeutics
MIAMI, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of...
Synlogic Provides Corporate Update and Outlook for 2024
04 janv. 2024 07h00 HE
|
Synlogic, Inc.
- Data review from pivotal Synpheny-3 study in PKU expected in H1 2024, with potential to expand study population to patients aged 12-17 years of age - - Top-line, Phase 3 data in PKU expected in H1...
Milestone Pharmaceuticals Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm
26 déc. 2023 10h55 HE
|
Block & Leviton LLP
BOSTON, Dec. 26, 2023 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Milestone Pharmaceuticals, Inc. (NASDAQ: MIST) for potential securities law violations. Investors who have lost money...
BioSenic progresse pour trouver les fonds nécessaires à la réalisation de son essai clinique clé sur la maladie chronique du greffon contre l'hôte
06 déc. 2023 01h00 HE
|
BioSenic
COMMUNIQUE DE PRESSE – INFORMATION PRIVILEGIÉE Biosenic signe un protocole d’accord avec SPRIM Global Investments (fonds TrialCap) pour un financement par emprunt de 8 millions d'USD et une...
BioSenic on its way to find the necessary funds to perform its key clinical trial on chronic Graft-versus-Host Disease
06 déc. 2023 01h00 HE
|
BioSenic
PRESS RELEASE – INSIDE INFORMATION Biosenic signs term sheet with SPRIM Global Investments (TrialCap fund) for up to USD 8 million debt financing and USD 800,000 equity investment...
BioSenic performs further analysis of its phase 2 clinical trial data, leading to an optimal administration scheme for its next late-stage trial of arsenic trioxide in cGvHD
27 sept. 2023 01h00 HE
|
BioSenic
BioSenic performs further analysis of its phase 2 clinical trial data, leading to an optimal administration scheme for its next late-stage trial of arsenic trioxide in cGvHD New post-hoc analysis...